Managing Alzheimer's Disease Now and in the Future: A Guide for Managed Care

You Are Invited to a One-time LIVE CME/CPE/CNE Webcast!

Managing Alzheimer's Disease Now and in the Future: A Guide for Managed Care

Live Webcast Date
October 31, 2017
12:30pm - 2:00pm ET

Jointly provided by
Impact Education, LLC    
This activity is supported by an educational grant from Biogen.


Register Now

Once registered you will receive login information and reminders via email.

HOT TOPICS
  • The clinical and economic burden of Alzheimer's Disease (AD)
  • Impact of care coordination in AD
  • Plan-wide initiatives to better coordinate care for AD among primary and ancillary providers
  • The clinical benefits of novel therapeutics addressing neuropsychological symptoms and disease modifying agents
EXPERT FACULTY
John Fox, MD, MHA
Senior Medical Director
Associate Vice President
Medical Affairs
Priority Health
James Kenney, Jr., RPh, MBA
Manager, Specialty and Pharmacy Contracts
Harvard Pilgrim Health Care
Marwan Sabbagh, MD, FAAN, CCRI
Karsten Solheim Chair for Dementia
Professor of Neurology
Director of the Alzheimer's and Memory Disorders Division
Barrow Neurological Institute
WHO SHOULD ATTEND?

This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, specialty pharmacists, medical directors, care managers, registered nurses, and other managed care and payer organization professionals.

STATEMENT OF NEED / PROGRAM OVERVIEW

Alzheimer's disease (AD) represents a significant driver of morbidity and mortality in the US, despite being overshadowed by other predominant conditions for which more effective treatment modalities exist. The incidence and mortality associated with the disease is increasing, indicating a key area of concern for managed care stakeholders. An estimated 5.3 million Americans were living with AD in 2015, and as many as 7.1 million will be diagnosed with the disease by 2025 according to the Alzheimer's Association. By 2050, that number may nearly triple to a projected 13.8 million, barring the development of medical breakthroughs to prevent or cure the disease. Unsurprisingly, this considerable burden of illness associated with AD is also accompanied by extensive direct and indirect costs.

This webcast will feature a multidisciplinary faculty panel who will present best practices for implementing collaborative treatment and patient management decisions that lead to optimal outcomes for patients with AD. This approach will enhance the audiences' ability to recommend and implement payer specific techniques to improve the continuity of care related to the impact of AD management strategies on clinical outcomes, value, and economic consequences for the entire health care system. The expert panel includes a leading neurologist in AD research and practice, a specialty pharmacy director, and a managed care medical director.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Characterize the clinical and economic burden of AD in terms of incidence and prevalence as well as direct and indirect costs
  • Describe various diagnostic tools for AD and evaluate their respective benefits and disadvantages for standardized use among network providers
  • Describe the impact of care coordination in AD in terms of patient quality of life and disease outcomes
  • Implement plan-wide initiatives to better coordinate care for AD among primary and ancillary providers in acute and long-term settings
  • Appraise the clinical benefits of novel therapeutics addressing neuropsychological symptoms and disease modifying agents in the management of AD
  • Develop formulary positioning and benefit design strategies for emerging AD therapies that encourage appropriate utilization while facilitating patient access and adherence
  • Outline the components and benefits of an effective medication therapy management (MTM) program for AD
  • Characterize the role of specialty pharmacy in supporting appropriate utilization and administration of emerging therapies for AD
ACCREDITATION INFORMATION
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - 0809-9999-17-826-L01-P

Type of Activity: Application

For Pharmacists: After receipt of a completed activity evaluation form you will be provided with instructions to have your credit immediately uploaded to CPE Monitor. Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.

Register Now